Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by motor symptoms such as tremors, rigidity, and bradykinesia, as well as non-motor symptoms including cognitive impairment and mood disorders. A hallmark of PD is the accumulation of alpha-synuclein, a presynaptic neuronal protein that aggregates to form Lewy bodies, leading to neuronal dysfunction and cell death. The study of alpha-synuclein and its pathological forms is crucial for understanding the etiology of PD and developing effective diagnostic and therapeutic strategies. Analytical techniques play a pivotal role in elucidating the structure, function, and aggregation mechanisms of alpha-synuclein. Biochemical methods such as Western blotting and enzyme-linked immunosorbent assay (ELISA) are employed to detect and quantify alpha-synuclein in biological samples, offering insights into its expression levels and post-translational modifications. Imaging techniques like immunohistochemistry and positron emission tomography (PET) allow for the visualization of alpha-synuclein aggregates in tissue samples and in vivo, respectively, facilitating the study of its spatial distribution and progression in PD Spectroscopic methods, including nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry, provide detailed structural information on alpha-synuclein and its isoforms, aiding in the identification of conformational changes associated with aggregation. Emerging techniques such as cryo-electron microscopy (Cryo-EM) and single-molecule fluorescence enable high-resolution structural analysis and real-time monitoring of alpha-synuclein aggregation dynamics, respectively. The application of these analytical techniques has significantly advanced our understanding of the pathophysiological role of alpha-synuclein in PD. They have contributed to the identification of potential biomarkers for early diagnosis and the evaluation of therapeutic interventions targeting alpha-synuclein aggregation. Despite technical limitations and challenges in clinical translation, ongoing advancements in analytical methodologies hold promise for improving the diagnosis, monitoring, and treatment of Parkinson’s disease through a deeper understanding of alpha-synuclein pathology.
References
[1]
Okpokoro, E., Lesosky, M., Osa-Afiana, C., Bada, F., Okwor, U., Odonye, G., et al. (2023) Prevalence and Risk Factors for Mycobacterium Tuberculosis Infection among Health Workers in HIV Treatment Centers in North Central, Nigeria. The American Journal of Tropical Medicine and Hygiene, 109, 60-68. https://doi.org/10.4269/ajtmh.22-0531
[2]
Jumare, J., Dakum, P., Sam-Agudu, N., Memiah, P., Nowak, R., Bada, F., et al. (2023) Prevalence and Characteristics of Metabolic Syndrome and Its Components among Adults Living with and without HIV in Nigeria: A Single-Center Study. BMC Endocrine Disorders, 23, Article No. 160. https://doi.org/10.1186/s12902-023-01419-x
[3]
Khan, A.U., Akram, M., Daniyal, M. and Zainab, R. (2018) Awareness and Current Knowledge of Parkinson’s Disease: A Neurodegenerative Disorder. International Journal of Neuroscience, 129, 55-93. https://doi.org/10.1080/00207454.2018.1486837
[4]
Castonguay, A., Gravel, C. and Lévesque, M. (2021) Treating Parkinson’s Disease with Antibodies: Previous Studies and Future Directions. Journal of Parkinson’s Disease, 11, 71-92. https://doi.org/10.3233/jpd-202221
[5]
Gannon, J., Bach, K., Cattaruzza, M.S., Bar-Zeev, Y., Forberger, S., Kilibarda, B., et al. (2023) Big Tobacco’s Dirty Tricks: Seven Key Tactics of the Tobacco Industry. Tobacco Prevention & Cessation, 9, 1-9. https://doi.org/10.18332/tpc/176336
[6]
Okpokoro, E., Okwor, U., Osa-Afiana, C., Odonye, G., Bada, F., Igbinomwanhia, V., et al. (2022) Tuberculosis Infection Control Practice among Antiretroviral (ART) Clinics in North Central Nigeria. Safety and Health at Work, 13, S108. https://doi.org/10.1016/j.shaw.2021.12.1092
[7]
Chiò, A., Canosa, A., Calvo, A., Moglia, C., Cicolin, A. and Mora, G. (2021) Developments in the Assessment of Non-Motor Disease Progression in Amyotrophic Lateral Sclerosis. Expert Review of Neurotherapeutics, 21, 1419-1440. https://doi.org/10.1080/14737175.2021.1984883
[8]
Conway, K.A., Lee, S., Rochet, J., Ding, T.T., Williamson, R.E. and Lansbury, P.T. (2000) Acceleration of Oligomerization, Not Fibrillization, Is a Shared Property of both α-Synuclein Mutations Linked to Early-Onset Parkinson’s Disease: Implications for Pathogenesis and Therapy. Proceedings of the National Academy of Sciences, 97, 571-576. https://doi.org/10.1073/pnas.97.2.571
[9]
Marino, B.L.B., de Souza, L.R., Sousa, K.P.A., Ferreira, J.V., Padilha, E.C., da Silva, C.H.T.P., et al. (2020) Parkinson’s Disease: A Review from Pathophysiology to Treatment. Mini-Reviews in Medicinal Chemistry, 20, 754-767. https://doi.org/10.2174/1389557519666191104110908
[10]
Cardinale, A., Calabrese, V., de Iure, A. and Picconi, B. (2021) Alpha-Synuclein as a Prominent Actor in the Inflammatory Synaptopathy of Parkinson’s Disease. International Journal of Molecular Sciences, 22, Article No. 6517. https://doi.org/10.3390/ijms22126517
[11]
Serratos, I.N., Hernández-Pérez, E., Campos, C., Aschner, M. and Santamaría, A. (2021) An Update on the Critical Role of α-Synuclein in Parkinson’s Disease and Other Synucleinopathies: From Tissue to Cellular and Molecular Levels. Molecular Neurobiology, 59, 620-642. https://doi.org/10.1007/s12035-021-02596-3
[12]
Brás, I.C. and Outeiro, T.F. (2021) Alpha-Synuclein: Mechanisms of Release and Pathology Progression in Synucleinopathies. Cells, 10, Article No. 375. https://doi.org/10.3390/cells10020375
[13]
Theillet, F., Binolfi, A., Bekei, B., Martorana, A., Rose, H.M., Stuiver, M., et al. (2016) Structural Disorder of Monomeric α-Synuclein Persists in Mammalian Cells. Nature, 530, 45-50. https://doi.org/10.1038/nature16531
[14]
Burré, J., Sharma, M., Tsetsenis, T., Buchman, V., Etherton, M.R. and Südhof, T.C. (2010) α-Synuclein Promotes SNARE-Complex Assembly in Vivo and in Vitro. Science, 329, 1663-1667. https://doi.org/10.1126/science.1195227
[15]
Zhu, M., Li, J. and Fink, A.L. (2003) The Association of α-Synuclein with Membranes Affects Bilayer Structure, Stability, and Fibril Formation. Journal of Biological Chemistry, 278, 40186-40197. https://doi.org/10.1074/jbc.m305326200
[16]
Spillantini, M.G., Schmidt, M.L., Lee, V.M., Trojanowski, J.Q., Jakes, R. and Goedert, M. (1997) α-Synuclein in Lewy bodies. Nature, 388, 839-840. https://doi.org/10.1038/42166
[17]
Watanabe-Nakayama, T., Ono, K., Itami, M., Takahashi, R., Teplow, D.B. and Yamada, M. (2016) High-Speed Atomic Force Microscopy Reveals Structural Dynamics of Amyloid β1-42 Aggregates. Proceedings of the National Academy of Sciences, 113, 5835-5840. https://doi.org/10.1073/pnas.1524807113
Ramis, R., Ortega-Castro, J., Vilanova, B., Adrover, M. and Frau, J. (2021) Cu2+, Ca2+, and Methionine Oxidation Expose the Hydrophobic α-Synuclein NAC Domain. International Journal of Biological Macromolecules, 169, 251-263. https://doi.org/10.1016/j.ijbiomac.2020.12.018
[20]
Bozelli, J.C., Kamski-Hennekam, E., Melacini, G. and Epand, R.M. (2021) α-Synuclein and Neuronal Membranes: Conformational Flexibilities in Health and Disease. Chemistry and Physics of Lipids, 235, Article ID: 105034. https://doi.org/10.1016/j.chemphyslip.2020.105034
[21]
Srinivasan, E., Chandrasekhar, G., Chandrasekar, P., Anbarasu, K., Vickram, A.S., Karunakaran, R., et al. (2021) Alpha-Synuclein Aggregation in Parkinson’s Disease. Frontiers in Medicine, 8, Article ID: 736978. https://doi.org/10.3389/fmed.2021.736978
[22]
Albert, K., Kälvälä, S., Hakosalo, V., Syvänen, V., Krupa, P., Niskanen, J., et al. (2022) Cellular Models of Alpha-Synuclein Aggregation: What Have We Learned and Implications for Future Study. Biomedicines, 10, Article No. 2649. https://doi.org/10.3390/biomedicines10102649
[23]
Menon, S., Armstrong, S., Hamzeh, A., Visanji, N.P., Sardi, S.P. and Tandon, A. (2022) Alpha-Synuclein Targeting Therapeutics for Parkinson’s Disease and Related Synucleinopathies. Frontiers in Neurology, 13, Article ID: 852003. https://doi.org/10.3389/fneur.2022.852003
[24]
Bisi, N., Feni, L., Peqini, K., Pérez-Peña, H., Ongeri, S., Pieraccini, S., et al. (2021) α-Synuclein: An All-Inclusive Trip around Its Structure, Influencing Factors and Applied Techniques. Frontiers in Chemistry, 9, Article ID: 666585. https://doi.org/10.3389/fchem.2021.666585
[25]
Huiting, W. and Bergink, S. (2020) Locked in a Vicious Cycle: The Connection between Genomic Instability and a Loss of Protein Homeostasis. Genome Instability & Disease, 2, 1-23. https://doi.org/10.1007/s42764-020-00027-6
[26]
Bernal-Conde, L.D., Ramos-Acevedo, R., Reyes-Hernández, M.A., Balbuena-Olvera, A.J., Morales-Moreno, I.D., Argüero-Sánchez, R., et al. (2020) Alpha-Synuclein Physiology and Pathology: A Perspective on Cellular Structures and Organelles. Frontiers in Neuroscience, 13, Article No. 1399. https://doi.org/10.3389/fnins.2019.01399
[27]
Teil, M., Arotcarena, M., Faggiani, E., Laferriere, F., Bezard, E. and Dehay, B. (2020) Targeting α-Synuclein for PD Therapeutics: A Pursuit on All Fronts. Biomolecules, 10, Article No. 391. https://doi.org/10.3390/biom10030391
[28]
Rashed, M.A.S., Abou-Deif, M.H., Khalil, K.M. and Mahmoud, F.E.S. (2021) Expression Levels of Heat Shock Proteins through Western Blot and Real-Time Polymerase Chain Reaction in Maize. Jordan Journal of Biological Sciences, 14, 671-676.
[29]
Hang, Y., Boryczka, J. and Wu, N. (2022) Visible-Light and Near-Infrared Fluorescence and Surface-Enhanced Raman Scattering Point-of-Care Sensing and Bio-Imaging: A Review. Chemical Society Reviews, 51, 329-375. https://doi.org/10.1039/c9cs00621d
[30]
Xiong, Y., Leng, Y., Li, X., Huang, X. and Xiong, Y. (2020) Emerging Strategies to Enhance the Sensitivity of Competitive ELISA for Detection of Chemical Contaminants in Food Samples. TrAC Trends in Analytical Chemistry, 126, Article ID: 115861. https://doi.org/10.1016/j.trac.2020.115861
[31]
Chang, C., Yang, S., Yang, C., Chang, C. and Wu, Y. (2020) Plasma and Serum Alpha-Synuclein as a Biomarker of Diagnosis in Patients with Parkinson’s Disease. Frontiers in Neurology, 10, Article No. 1388. https://doi.org/10.3389/fneur.2019.01388
[32]
Petricca, L., Chiki, N., Hanna-El-Daher, L., Aeschbach, L., Burai, R., Stoops, E., et al. (2022) Comparative Analysis of Total Alpha-Synuclein (αsyn) Immunoassays Reveals That They Do Not Capture the Diversity of Modified αsyn Proteoforms. Journal of Parkinson’s Disease, 12, 1449-1462. https://doi.org/10.3233/jpd-223285
[33]
Xue, Z., Wu, Y., Gao, Q., Zhao, L. and Xu, Y. (2020) Automated Classification of Protein Subcellular Localization in Immunohistochemistry Images to Reveal Biomarkers in Colon Cancer. BMC Bioinformatics, 21, Article No. 398. https://doi.org/10.1186/s12859-020-03731-y
[34]
Koss, D.J., Erskine, D., Porter, A., Palmoski, P., Menon, H., Todd, O.G.J., et al. (2022) Nuclear Alpha-Synuclein Is Present in the Human Brain and Is Modified in Dementia with Lewy Bodies. Acta Neuropathologica Communications, 10, Article No. 98. https://doi.org/10.1186/s40478-022-01403-x
[35]
Moors, T.E., Maat, C.A., Niedieker, D., Mona, D., Petersen, D., Timmermans-Huisman, E., et al. (2021) The Subcellular Arrangement of Alpha-Synuclein Proteoforms in the Parkinson’s Disease Brain as Revealed by Multicolor STED Microscopy. Acta Neuropathologica, 142, 423-448. https://doi.org/10.1007/s00401-021-02329-9
[36]
Zoey, F.L., Palanivel, M., Padmanabhan, P. and Gulyás, B. (2021) Parkinson’s Disease: A Nanotheranostic Approach Targeting Alpha-Synuclein Aggregation. Frontiers in Cell and Developmental Biology, 9, Article ID: 707441. https://doi.org/10.3389/fcell.2021.707441
[37]
Reif, B., Ashbrook, S.E., Emsley, L. and Hong, M. (2021) Solid-State NMR Spectroscopy. Nature Reviews Methods Primers, 1, Article No. 2. https://doi.org/10.1038/s43586-020-00002-1
[38]
Stephens, A.D., Zacharopoulou, M., Moons, R., Fusco, G., Seetaloo, N., Chiki, A., et al. (2020) Extent of N-Terminus Exposure of Monomeric Alpha-Synuclein Determines Its Aggregation Propensity. Nature Communications, 11, Article No. 2820. https://doi.org/10.1038/s41467-020-16564-3
[39]
Azevedo, R., Jacquemin, C., Villain, N., Fenaille, F., Lamari, F. and Becher, F. (2022) Mass Spectrometry for Neurobiomarker Discovery: The Relevance of Post-Translational Modifications. Cells, 11, Article No. 1279. https://doi.org/10.3390/cells11081279
[40]
Oliveira, L.M.A., Gasser, T., Edwards, R., Zweckstetter, M., Melki, R., Stefanis, L., et al. (2021) Alpha-Synuclein Research: Defining Strategic Moves in the Battle against Parkinson’s Disease. NPJ Parkinson’s Disease, 7, Article No. 65. https://doi.org/10.1038/s41531-021-00203-9
[41]
Namba, K. and Makino, F. (2022) Recent Progress and Future Perspective of Electron Cryomicroscopy for Structural Life Sciences. Microscopy, 71, i3-i14. https://doi.org/10.1093/jmicro/dfab049
[42]
Ha, T., Kaiser, C., Myong, S., Wu, B. and Xiao, J. (2022) Next Generation Single-Molecule Techniques: Imaging, Labeling, and Manipulation in Vitro and in Cellulo. Molecular Cell, 82, 304-314. https://doi.org/10.1016/j.molcel.2021.12.019
[43]
Vidović, M. and Rikalovic, M.G. (2022) Alpha-Synuclein Aggregation Pathway in Parkinson’s Disease: Current Status and Novel Therapeutic Approaches. Cells, 11, Article No. 1732. https://doi.org/10.3390/cells11111732
[44]
Lashuel, H.A. (2020) Do Lewy Bodies Contain Alpha-Synuclein Fibrils? And Does It Matter? A Brief History and Critical Analysis of Recent Reports. Neurobiology of Disease, 141, Article ID: 104876. https://doi.org/10.1016/j.nbd.2020.104876
[45]
Magalhães, P. and Lashuel, H.A. (2022) Opportunities and Challenges of Alpha-Synuclein as a Potential Biomarker for Parkinson’s Disease and Other Synucleinopathies. NPJ Parkinson’s Disease, 8, Article No. 93. https://doi.org/10.1038/s41531-022-00357-0
[46]
Condrat, C.E., Thompson, D.C., Barbu, M.G., Bugnar, O.L., Boboc, A., Cretoiu, D., et al. (2020) Mirnas as Biomarkers in Disease: Latest Findings Regarding Their Role in Diagnosis and Prognosis. Cells, 9, Article No. 276. https://doi.org/10.3390/cells9020276
[47]
Anjo, S.I., dos Santos, P.V., Rosado, L., Baltazar, G., Baldeiras, I., Pires, D., et al. (2020) A Different Vision of Translational Research in Biomarker Discovery: A Pilot Study on Circulatory Mitochondrial Proteins as Parkinson’s Disease Potential Biomarkers. Translational Neurodegeneration, 9, Article No. 11. https://doi.org/10.1186/s40035-020-00188-0
[48]
Barkovits, K., Kruse, N., Linden, A., Tönges, L., Pfeiffer, K., Mollenhauer, B., et al. (2020) Blood Contamination in CSF and Its Impact on Quantitative Analysis of Alpha-Synuclein. Cells, 9, Article No. 370. https://doi.org/10.3390/cells9020370
[49]
Golan, H., Volkov, O. and Shalom, E. (2022) Nuclear Imaging in Parkinson’s Disease: The Past, the Present, and the Future. Journal of the Neurological Sciences, 436, Article ID: 120220. https://doi.org/10.1016/j.jns.2022.120220
Davis, K.D., Aghaeepour, N., Ahn, A.H., Angst, M.S., Borsook, D., Brenton, A., et al. (2020) Discovery and Validation of Biomarkers to Aid the Development of Safe and Effective Pain Therapeutics: Challenges and Opportunities. Nature Reviews Neurology, 16, 381-400. https://doi.org/10.1038/s41582-020-0362-2
[52]
Nwabufo, C.K. and Aigbogun, O.P. (2022) Diagnostic and Therapeutic Agents That Target Alpha-Synuclein in Parkinson’s Disease. Journal of Neurology, 269, 5762-5786. https://doi.org/10.1007/s00415-022-11267-9
[53]
Alzghool, O.M., van Dongen, G., van de Giessen, E., Schoonmade, L. and Beaino, W. (2022) α‐Synuclein Radiotracer Development and in Vivo Imaging: Recent Advancements and New Perspectives. Movement Disorders, 37, 936-948. https://doi.org/10.1002/mds.28984
[54]
Polissidis, A., Petropoulou-Vathi, L., Nakos-Bimpos, M. and Rideout, H.J. (2020) The Future of Targeted Gene-Based Treatment Strategies and Biomarkers in Parkinson’s Disease. Biomolecules, 10, Article No. 912. https://doi.org/10.3390/biom10060912
[55]
O’Hara, D.M., Kalia, S.K. and Kalia, L.V. (2020) Methods for Detecting Toxic α-Synuclein Species as a Biomarker for Parkinson’s Disease. Critical Reviews in Clinical Laboratory Sciences, 57, 291-307. https://doi.org/10.1080/10408363.2019.1711359
[56]
Rideout, H.J., Chartier-Harlin, M., Fell, M.J., Hirst, W.D., Huntwork-Rodriguez, S., Leyns, C.E.G., et al. (2020) The Current State-of-the-Art of Lrrk2-Based Biomarker Assay Development in Parkinson’s Disease. Frontiers in Neuroscience, 14, Article No. 865. https://doi.org/10.3389/fnins.2020.00865
[57]
Koga, S., Sekiya, H., Kondru, N., Ross, O.A. and Dickson, D.W. (2021) Neuropathology and Molecular Diagnosis of Synucleinopathies. Molecular Neurodegeneration, 16, Article No. 83. https://doi.org/10.1186/s13024-021-00501-z
[58]
Sobsey, C.A., Ibrahim, S., Richard, V.R., Gaspar, V., Mitsa, G., Lacasse, V., et al. (2020) Targeted and Untargeted Proteomics Approaches in Biomarker Development. Proteomics, 20, Article ID: 1900029. https://doi.org/10.1002/pmic.201900029
[59]
Hendrix, S.B., Mogg, R., Wang, S.J., Chakravarty, A., Romero, K., Dickson, S.P., et al. (2021) Perspectives on Statistical Strategies for the Regulatory Biomarker Qualification Process. Biomarkers in Medicine, 15, 669-684. https://doi.org/10.2217/bmm-2020-0523
[60]
Kaur, A., New, E.J. and Sunde, M. (2020) Strategies for the Molecular Imaging of Amyloid and the Value of a Multimodal Approach. ACS Sensors, 5, 2268-2282. https://doi.org/10.1021/acssensors.0c01101
[61]
MacDougall, G., Brown, L.Y., Kantor, B. and Chiba-Falek, O. (2021) The Path to Progress Preclinical Studies of Age-Related Neurodegenerative Diseases: A Perspective on Rodent and hiPSC-Derived Models. Molecular Therapy, 29, 949-972. https://doi.org/10.1016/j.ymthe.2021.01.001
[62]
Cassotta, M. (2022) The Future of Parkinson’s Disease Research: A New Paradigm of Human-Specific Investigation Is Necessary… and Possible. ALTEX, 39, 694-709. https://doi.org/10.14573/altex.2203161
